Trials / Completed
CompletedNCT00230958
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive
Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (planned)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before recieved treatment.
Detailed description
Compare the efficacy and safety of viramidine 600 mg BID versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2b to treatment-naive patients with chronic hepatitis C (CHC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Viramidine | |
| DRUG | Ribavirin | |
| DRUG | pegylated interferon alfa-2b |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2005-10-03
- Last updated
- 2012-06-22
Source: ClinicalTrials.gov record NCT00230958. Inclusion in this directory is not an endorsement.